CCL21 and neoplasm: - Tumor angiogenic vessel pericyte reconstitution (55)- Reducing tumor vascular flow inefficiency (i.e.,”normalization” by VEGF blockade) (64)- Drive spatial expression of effector T-cell “long-distance” chemokine gradients: e.g., DC CCL21 driving CTLs (20, 122)- Restoring sphingosine-1 phosphate (S1P) function for augmented lymph node T-cell traffic kinetics (128)